Sorafenib With Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study

Cancers - Switzerland
doi 10.3390/cancers11070985
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Sorafenib Alone Versus Sorafenib Combined With Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses

Radiology
Nuclear MedicineRadiologyImaging
2013English

Advanced Recurrent Hepatocellular Carcinoma: Treatment With Sorafenib Alone or in Combination With Transarterial Chemoembolization and Radiofrequency Ablation

Radiology
Nuclear MedicineRadiologyImaging
2018English

Sorafenib With or Without Concurrent Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma: A Phase III STAH Trial

Journal of Hepatology
Hepatology
2019English

Medium or Large Hepatocellular Carcinoma: Sorafenib Combined With Transarterial Chemoembolization and Radiofrequency Ablation

Radiology
Nuclear MedicineRadiologyImaging
2018English

Transcatheter Arterial Chemoembolization After Stopping Sorafenib Therapy for Advanced Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2017English

Retrospective Analysis of Transarterial Chemoembolization and Sorafenib in Chinese Patients With Unresectable and Recurrent Hepatocellular Carcinoma

Oncotarget
Oncology
2016English

Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis

Journal of Hepatology
Hepatology
2019English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Sorafenib With Interleukin-2 vs Sorafenib Alone in Metastatic Renal Cell Carcinoma: The ROSORC Trial

British Journal of Cancer
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy